בית › סרטן אנדומטריאלי › מסצ'וסטס › Boston
מחקרים קליניים עבור סרטן אנדומטריאלי ב-Boston, MA
50 מחקרים עבור סרטן אנדומטריאלי מחפשים משתתפים באתרים ב-Boston ובסביבתה (בטווח של כ-30 מייל). פתחו מחקר כדי לראות מי יכול להשתתף וכיצד ליצור קשר עם צוות המחקר.
טקסט רשמי של המחקר (באנגלית)
מגייסים משתתפים למחקר כאן? הציגו אותו בראש העמוד – $99 ל-30 ימים →
Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer
מגייסשלב 3
- Dana-Farber Cancer Institute, Boston
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
מגייסשלב 2
- Tufts Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors
מגייסשלב 1/2
- Research Site, Boston
A Study of PHST001 in Advanced Solid Tumors
מגייסשלב 1
- Dana Farber Cancer Institute, Boston
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
מגייסשלב 1/2
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute, Boston
A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
מגייסשלב 2
- Dana-Farber Cancer Institute - Oncology Department, Boston
Distance-Based Exercise to Preserve Function and Prevent Disability
מגייס
- Dana-Farber Cancer Institute, Boston
A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
מגייסשלב 1
- Dana Farber Cancer Institute, Boston
Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers
מגייסשלב 1/2
- Massachusetts General Hospital, Boston
- Dana Farber / Harvard Cancer Center, Boston
Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors
מגייסשלב 1
- Research Site, Boston
Adjuvant Therapy in POLE-Mutated and p53-Wildtype/NSMP Early Stage Endometrial Cancer RAINBO BLUE & TAPER
מגייסשלב 2
- Massachusetts General Hospital Cancer Center, Boston
A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or Ubamatamab
מגייסשלב 1/2
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute Brookline Avenue, Boston
A Study of LY4257496 in Participants With Cancer (OMNIRAY)
מגייסשלב 1
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
מגייסשלב 1/2
- Dana Farber Cancer Institute, Boston
Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
מגייסשלב 1
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)
מגייסשלב 3
- Tufts Medical Center ( Site 6052), Boston
A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
מגייסשלב 1/2
- Massachusetts General Hospital, Boston
ALPINE: Maintenance Letrozole/Abemaciclib
מגייסשלב 2
- Beth Israel Deaconess Medical Center, Boston
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
מגייסשלב 1/2
- Research Site, Boston
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
מגייסשלב 1
- Dana Farber Cancer Institute, Boston
Phase 1 Study to Assess Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of ARR-002 in Advanced or Metastatic Ovarian or Endometrial Cancer.
מגייסשלב 1
- Dana-Farber Cancer Institute, Boston
A Phase 1 Study of CTIM-76 in Patients With Recurring Ovarian Cancer and Other Advanced Solid Tumors
מגייסשלב 1
- Dana-Farber Cancer Institute, Boston
DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer
מגייסשלב 3
- Research Site, Boston
Concurrent Laparoscopic Hysterectomy and Weight Loss Surgery in Obese Patients With Endometrial Carcinoma or Endometrial Intraepithelial Neoplasia
מגייס
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
A Study of STRO-004 in Adults With Refractory/Recurrent Metastatic Cancer
מגייסשלב 1
- Mass General Cancer Center, Boston
A Study of Mutant Selective-Inhibitor (CGT6297), in Patients With Advanced Solid Tumors
מגייסשלב 1
- Dana-Farber Cancer Institute, Boston
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
מגייסשלב 1/2
- Dana-Farber Cancer Institute, Boston
A Phase 2 Study of ACR-368 in Endometrial Adenocarcinoma
מגייסשלב 2
- Dana Farber Cancer Institute, Boston
A Phase 1 Study of LNCB74 in Advanced Solid Tumors
מגייסשלב 1
- Dana Farber Cancer Institute, Boston
A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
מגייסשלב 1/2
- Massachusetts General Hospital, Boston
A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors
מגייסשלב 1
- Normunity Investigational Site, Boston
- Normunity Investigational Site, Boston
FOG-001 in Locally Advanced or Metastatic Solid Tumors
מגייסשלב 1/2
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute, Boston
A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
מגייסשלב 1/2
- Massachusetts General Hospital Cancer Center, Boston
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
מגייסשלב 1/2
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute, Boston
First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
מגייסשלב 1/2
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
A Phase 1 Dose-escalation Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation
מגייסשלב 1
- Mass General Brigham Cancer Institute at Massachusetts General Hospital, Boston
A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
מגייסשלב 1/2
- Beth Israel Deaconess Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors
מגייסשלב 1/2
- Beth Israel Deaconess Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
A Study of LY4175408 in Participants With Advanced Cancer
מגייסשלב 1
- Massachusetts General Hospital, Boston
RESOLVE: Abemaciclib + Letrozole +/- Metformin or Gedatolisib in Endometrial Cancer
מגייסשלב 2
- Massachusetts General Hospital Cancer Center, Boston
- Beth Israel Deaconess Medical Center (BIDMC), Boston
- Dana Farber Cancer Institute, Boston
Menstrual Cup for Early Endometrial Cancer Detection in Lynch Syndrome
מגייסמתנדבים בריאים מוזמנים
- Dana-Farber Cancer Institute, Boston
A Phase 1/1B Study of ST-01156, a Small Molecule RBM39 Degrader, in Patients With Advanced Solid Malignancies
מגייסשלב 1
- Mass General Brigham Cancer Institute, Boston
- Dana Farber Cancer Institute, Boston
Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
מגייסשלב 1/2
- Massachusetts General Hospital, Boston
A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies
מגייסשלב 1/2
- Massachusetts General Hospital, Boston
Exercise as a Preventive Agent to Combat Immobility in Patients With Ovarian or Endometrial Cancers Receiving Chemotherapy
מגייס
- Dana Farber Cancer Institute, Boston
Avelumab and M1774 in ARID1A-mutated Endometrial Cancer
מגייסשלב 2
- Dana-Farber Cancer Institute, Boston
- Brigham and Women's Hospital, Boston
Belzutifan in Recurrent Clear Cell Carcinoma of Gynecologic Origin
מגייסשלב 2
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors
מגייסשלב 1/2
- Dana Farber Cancer Institute, Boston
A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies
מגייסשלב 1/2
- Massachusetts General Hospital, Boston
Comprehensive Outcomes for After Cancer Health
מגייסמתנדבים בריאים מוזמנים
- Dana Farber Cancer Institute, Boston
מחקרים עבור סרטן אנדומטריאלי בערים אחרות
- Houston, TX68 מחקרים
- New York City, NY52 מחקרים
- Arlington, VA39 מחקרים
- Nashville, TN38 מחקרים
- Los Angeles, CA34 מחקרים
- St. Louis, MO29 מחקרים
- Philadelphia, PA28 מחקרים
- San Antonio, TX27 מחקרים
- Columbus, OH25 מחקרים
- Oklahoma City, OK25 מחקרים
- Chicago, IL25 מחקרים
- Queens, NY25 מחקרים
מחקרים אחרים ב-Boston
- סרטן השד112 מחקרים
- סרטן ריאות לא תא קטן90 מחקרים
- סרטן (כל הסוגים)85 מחקרים
- סרטן גרורתי63 מחקרים
- סרטן המעי הגס והחלחולת63 מחקרים
- סרטן הריאה62 מחקרים
- סרטן השחלות61 מחקרים
- סרטן הערמונית59 מחקרים
- דיכאון52 מחקרים
- אי-ספיקת לב44 מחקרים
- לוקמיה מיאלואידית חריפה44 מחקרים
- סרטן הלבלב43 מחקרים
מקור: ClinicalTrials.gov, המידע אוחזר בתאריך 6 באוק׳ 2026. כל מחקר מגדיר את קריטריוני ההשתתפות שלו; צוות המחקר קובע מי יכול להשתתף.